Is Cochlear Limited (CHEOY) a Buy, Sell, or Hold?
OTC : CHEOY
Cochlear Limited
$41.95 USD
-$1.28 (-2.96%)
- Volume
- 3.87K
- Average Volume
- 85.56K
- Market Capitalization
- $5.49B
- P/E Ratio
- 22.64
- Dividend Yield
- 3.60%
- Price Target
- $117.00
- Year High
- $105.60
- Year Low
- $31.82
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.81
- Current Ratio
- $2.46
Company Overview
OTC
Diggory William Howitt
Medical - Devices
Healthcare
CHEOY
5500
AU
USD
Liquidity Metrics
0.22
2.46
1.44
0.33
0.81
Sales & Valuation
$2.34B
3.31
4.04
38.86
1.54
Profitability
$2.97
$388.9M
14.62%
19.28%
17.76%
12.36%
P/E Metrics
22.64
-3.46
-3.46
Analyst Price Target & Rating
$117.00
$117.00
$117.00
3/5
0 Analysts
-64.15%
Poll Results
About Cochlear Limited (OTC:CHEOY) Stock
Cochlear Limited is a global healthcare company specializing in advanced auditory solutions. It develops and manufactures surgically implanted hearing devices for individuals of all ages, from children to adults, across the world. The company's diverse product range features cochlear implant systems, enhanced sound processor upgrades, bone conduction technology, and a variety of complementary accessories and related items. Founded in 1981, Cochlear Limited is headquartered in Sydney, Australia. ...
2026-07-14 09:17:00
Mean CNC word recognition scores for Stage 1 cohort improved to 53.2% at 12 months from 15.2% pre-implantation, a 38.0 percentage point gain that continued to build on the 24.0 percentage point improvement reported at 6 months White Bear Lake, Minnesota--(Newsfile Corp. - July 14, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced positive 12-month data from the first 10 participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. The Stage 1 cohort demonstrated a mean Consonant-Nucleus-Consonant ("CNC") word recognition score of 53.2% at their 12-month visits, up from a mean pre-implantation baseline of 15.2% — a 38.0 percentage point improvement.
Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants
2026-05-29 14:13:00
During Better Hearing and Speech Month, understanding MRI compatibility is an important part of long-term hearing care LONE TREE, Colo., May 29, 2026 /PRNewswire/ -- May is Better Hearing and Speech Month, a month dedicated to raising awareness about the importance of hearing health.
2026-05-11 08:00:00
Company Completes Historic Trial Enrollment, Secures Transformational Financing, and Sees Promising Early Clinical Data Presented at Industry Conferences White Bear Lake, Minnesota--(Newsfile Corp. - May 11, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported first quarter 2026 results and landmark achievements that advance the Company another step closer toward commercialization of its investigational Acclaim® cochlear implant. "The first quarter of 2026 marked a transformative period for Envoy Medical, highlighted by the completion of enrollment in our pivotal clinical trial and the successful execution of a significant financing," said Brent Lucas, Chief Executive Officer of Envoy Medical.
2026-04-29 10:30:00
DURHAM, N.C.--(BUSINESS WIRE)-- #ACIA2026--Hearing implant leader MED-EL USA is announcing two upcoming symposia at CI2026, the annual meeting of the American Cochlear Implant Association (ACIA) in Chicago. The meeting also celebrates the recent U.S. Food and Drug Administration (FDA) approval of an expanded indication for MED-EL cochlear implants for children seven months and older with bilateral sensorineural hearing loss (SNHL). MED-EL's cochlear implant system is the only FDA-approved option for infant.
Cochlear Limited (CHEOY) Q3 2026 Sales/Trading Call Transcript
2026-04-22 18:00:39
Cochlear Limited (CHEOY) Q3 2026 Sales/Trading Call Transcript
Australia's Cochlear crashes 40% after flagging weak demand and Mideast war impact
2026-04-22 04:32:06
Cochlear shares crashed nearly 41% on Wednesday in a record daily fall, after the Australian hearing implants maker slashed its forecast for annual earnings, citing weak trading conditions and uncertainty stoked by the Middle East war.
Frequently Asked Questions
-
What is the current Cochlear Limited (CHEOY) stock price?
-
Cochlear Limited(OTC:CHEOY) stock price is $41.95 in the last trading session. During the trading session, CHEOY stock reached the peak price of $105.6 while $31.82 was the lowest point it dropped to. The percentage change in CHEOY stock occurred in the recent session was --2.96% while the dollar amount for the price change in CHEOY stock was -$1.28.
-
CHEOY's industry and sector of operation?
-
The OTC listed CHEOY is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of CHEOY?
-
Kristina Devon | Vice President of Corporate Strategy & Investor Relations
Sarah Thom | Chief Financial Officer
Dean Phizacklea | Senior Vice President of Global Strategic Marketing
Jan Janssen Elec | Chief Technology Officer
Rob McGrory | Group General Counsel & Company Secretary -
How many employees does CHEOY have?
-
Number of CHEOY employees currently stands at 5500. CHEOY operates from 1 University Avenue, Sydney, NSW 2109, AU.
-
Link for CHEOY official website?
-
Official Website of CHEOY is: https://www.cochlear.com
-
How do I contact CHEOY?
-
CHEOY could be contacted at phone #61 2 9428 6555 and can also be accessed through its website. CHEOY operates from 1 University Avenue, Sydney, NSW 2109, AU.
-
How many shares of CHEOY are traded daily?
-
The average number of CHEOY shares traded daily for last 3 months was 85.56K.
-
What is the market cap of CHEOY currently?
-
The market value of CHEOY currently stands at $5.49B with its latest stock price at $41.95